The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment
Open accessAbstract
Hypoxia exists to some degree in most solid tumors due to inadequate oxygen delivery of the abnormal vasculature which cannot meet the demands of the rapidly proliferating cancer cells. The levels of oxygenation within the same tumor are highly variable from one area to another and can change over time. Tumor hypoxia is an important impediment to effective cancer therapy. In radiotherapy, the primary mechanism is the creation of reactive oxygen species; hypoxic tumors are therefore radiation resistant. A number of chemotherapeutic drugs have been shown to be less effective when exposed to a hypoxic environment which can lead to further disease progression. Hypoxia is also a potent barrier to effective immunotherapy in cancer treatment. Because of the recognition of hypoxia as an important barrier to cancer treatment, a variety of approaches have been undertaken to overcome or reverse tumor hypoxia. Such approaches have included breathing hyperbaric oxygen, artificial hemoglobins, allosteric hemoglobin modifiers, hypoxia activated prodrugs and fluorocarbons (FCs). These approaches have largely failed due to limited efficacy and/or adverse side effects. Oxygen therapeutics, based on liquid FCs, can potentially increase the oxygen-carrying capacity of the blood to reverse tumor hypoxia. Currently, at least two drugs are in clinical trials to reverse tumor hypoxia; one of these is designed to improve permeability of oxygen into the tumor tissue and the other is based upon a low boiling point FC that transports higher amounts of oxygen per gram than previously tested FCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662 · cited 1×
“tissue.(15) Profound hypoxia promotes changes in the proteome and genome.”
BackgroundGray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Hypoxia, DNA repair and genetic instability
Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140
Cheng, Y., Cheng, H., Jiang, C., Qiu, X., Wang, K., Huan, W., Yuan, A., Wu, J., & Hu, Y. (2015) · Nature Communications · doi:10.1038/ncomms9785 · Cited by 941
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Detection and Characterization of Tumor Hypoxia Using pO 2 Histography
Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Moulder, J. E., & Rockwell, S. (1984) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(84)90301-8 · Cited by 606
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
KOMOTAR, R. J., WILSON, D. A., & CONNOLLY, E. S. (2005) · Neurosurgery · doi:10.1093/neurosurgery/57.1.n7a · Cited by 570
Teicher, B. A., Lazo, J. S., & Sartorelli, A. C. (1981) · PubMed · Cited by 555
Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise
Rockwell, S., Dobrucki, I., Kim, E., Marrison, S., & Vu, V. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167087 · Cited by 511
Tumor hypoxia and malignant progression
Vaupel, P., Mayer, A., & Höckel, M. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)81023-1 · Cited by 496
Riess, J. G. (2005) · Artificial Cells, Blood Substitutes, and Biotechnology · doi:10.1081/bio-200046659 · Cited by 361
Tumor Hypoxia in Cancer Therapy
Brown, J. M. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35015-5 · Cited by 359
Manipulating tumor hypoxia toward enhanced photodynamic therapy (PDT)
Dang, J., He, H., Chen, D., & Yin, L. (2017) · Biomaterials Science · doi:10.1039/c7bm00392g · Cited by 317
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors
Rampling, R., Cruickshank, G., Lewis, A. D., Fitzsimmons, S. A., & Workman, P. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90432-4 · Cited by 304
Maity, A. M., Pore, N., Lee, J. S. H., Solomon, D., & O’Rourke, D. M. (2000) · PubMed · Cited by 302
Significance of nitroimidazole compounds and hypoxia‐inducible factor‐1 for imaging tumor hypoxia
Kizaka‐Kondoh, S., & Konse‐Nagasawa, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01195.x · Cited by 255
Teicher, B. A., Holden, S. A., Al-Achi, A., & Herman, T. S. (1990) · PubMed · Cited by 225
Sitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Belikoff, B., Schreiber, T. H., Sethumadhavan, S., Abbott, R., Philbrook, P., Thayer, M., Shujia, D., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1189-3 · Cited by 211
Potential bioreductive alkylating agents. 1. Benzoquinone derivatives
Lin, A. J., Cosby, L. A., Shansky, C. W., & Sartorelli, A. C. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00282a011 · Cited by 198
Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases
Suh, J. H., Stea, B., Nabid, A., Kresl, J. J., Fortin, A., Mercier, J.-P., Senzer, N., Chang, E. L., Boyd, A. P., Cagnoni, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1768 · Cited by 195
The Clinical Significance of Hypoxia in Human Cancers
Dhani, N., Fyles, A., Hedley, D., & Milosevic, M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.11.002 · Cited by 188
Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix
Watson, E. R., Hainan, K. E., Dische, S., Saunders, M. I., Cade, I. S., McEwen, J. B., Wiernik, G., Perrins, D. J. D., & Sutherland, I. (1978) · The British Journal of Radiology · doi:10.1259/0007-1285-51-611-879 · Cited by 187
Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the bladder
Cade, I. S., McEwen, J. B., Dische, S., Saunders, M. I., Watson, E. R., Halnan, K. E., Wiernik, G., Perrins, D. J. D., & Sutherland, I. (1978) · The British Journal of Radiology · doi:10.1259/0007-1285-51-611-876 · Cited by 182
Hypoxia and hypoxia inducible factors in tumor metabolism
Zeng, W., Liu, P., Pan, W., Singh, S. R., & Wei, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.01.032 · Cited by 170
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Guise, C. P., Mowday, A. M., Ashoorzadeh, A., Yuan, R., Lin, W.-H., Wu, D.-H., Smaill, J. B., Patterson, A. V., & Ding, K. (2014) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10285 · Cited by 170
Collingridge, D. R., Piepmeier, J. M., Rockwell, S., & Knisely, J. P. S. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00121-8 · Cited by 164
Wouters, A., Pauwels, B., Lardon, F., & Vermorken, J. B. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-690 · Cited by 164
O'Connor, J. P. B., Boult, J. K. R., Jamin, Y., Babur, M., Finegan, K. G., Williams, K. J., Little, R. A., Jackson, A., Parker, G. J. M., Reynolds, A. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2062 · Cited by 161
Effects of hypoxia on human cancer cell line chemosensitivity
Strese, S., Fryknäs, M., Larsson, R. L., & Gullbo, J. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-331 · Cited by 157
Hatfield, S. M., & Sitkovsky, M. V. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.06.009 · Cited by 155
Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours
Stępień, K., Ostrowski, R. P., & Matyja, E. (2016) · Medical Oncology · doi:10.1007/s12032-016-0814-0 · Cited by 148
Studies of Tissue PO2 in Normal and Pathological Human Brain Cortex
Meixensberger, J., Dings, J. T. A., Kuhnigk, H., & Roosen, K. (1993) · Springer eBooks · doi:10.1007/978-3-7091-9302-0_10 · Cited by 140
Change of Oxygen Pressure in Glioblastoma Tissue Under Various Conditions
Beppu, T., Kamada, K., Yoshida, Y., Arai, H., Ogasawara, K., & Ogawa, A. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1015832726054 · Cited by 123
Geometric Resistance and Microvascular Network Architecture of Human Colorectal Carcinoma
Less, J. R., Mc, P., Skalak, T. C., Wolmark, N., & Jain, R. K. (1997) · Microcirculation · doi:10.3109/10739689709148315 · Cited by 110
The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation
Brizel, D. M., Lin, S., Johnson, J., Brooks, J., Dewhirst, M. W., & Piantadosi, C. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.474 · Cited by 107
Tissue factor, angiogenesis and tumour progression
Bluff, J. E., Brown, N. J., Reed, M., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr1871 · Cited by 106
A clinical trial of Fluosol DA 20% in advanced squamous cell carcinoma of the head and neck
Rose, C., Lustig, R. A., Mcintosh, N. L., & Teicher, B. A. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90164-1 · Cited by 77
White, D. A., Zhang, Z., Li, L., Gerberich, J., Stojadinović, S., Peschke, P., & Mason, R. P. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.003 · Cited by 69
Johnson, J. L. H., Dolezal, M. C., Kerschen, A., Matsunaga, T. O., & Unger, E. C. (2009) · Artificial Cells Blood Substitutes and Biotechnology · doi:10.1080/10731190903043192 · Cited by 63
Self-citationTargeting Tumor Hypoxia With Hypoxia-Activated Prodrugs
Yeh, J. J., & Kim, W. Y. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0759 · Cited by 61
Baker, A. F., Koh, M. Y., Williams, R. R., James, B. P., Wang, H., Tate, W. R., Gallegos, A. C., Hoff, D. D. V., Han, H., & Powis, G. (2008) · Pancreas · doi:10.1097/mpa.0b013e31815929fe · Cited by 55
Yao, X., Ping, Y., Chen, J., Chen, D.-L., Xu, C.-P., Zheng, J., Wang, J. M., & Bian, X. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9443-y · Cited by 52
Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme
Gainer, J. L., Sheehan, J. P., Larner, J. M., & Jones, D. R. (2016) · Journal of neurosurgery · doi:10.3171/2016.3.jns152693 · Cited by 47
A Surgical View of Photodynamic Therapy in Oncology: A Review
Dixon, K., Gibbins, S., & Moghissi, K. (2015) · The Surgery Journal · doi:10.1055/s-0035-1565246 · Cited by 45
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
Sun, S., Lee, D., Lee, N. P. Y., Pu, J. K.-S., Wong, T., Lui, W., Fung, C. F., & Leung, G. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0923-3 · Cited by 44
Murayama, C., Kawaguchi, A. T., Ishikawa, K., Kamijo, A., Kato, N., Ohizumi, Y., Sadahiro, S., & Haida, M. (2012) · Artificial Organs · doi:10.1111/j.1525-1594.2011.01418.x · Cited by 43
Leone, R. D., Horton, M. R., & Powell, J. D. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.014 · Cited by 42
Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways
Wachsberger, P. R., Burd, R., & Dicker, A. P. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.06.007 · Cited by 42
Clinical trials of radiotherapy in hyperbaric oxygen at Portsmouth, 1964–1976
Cade, I. S., & McEwen, J. B. (1978) · Clinical Radiology · doi:10.1016/s0009-9260(78)80081-6 · Cited by 42
Ascierto, P. A., Addeo, R., Cartenì, G., Daniele, B., Laurentis, M. D., Ianniello, G. P., Morabito, A., Palmieri, G., Pepe, S., Perrone, F., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0291-1 · Cited by 39
Johnson, J. L. H., Leos, R. A., Baker, A. F., & Unger, E. C. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2015.1903 · Cited by 36
Self-citationUpdate on positron emission tomography for imaging of prostate cancer
Kitajima, K., Murphy, R. C., Nathan, M. A., & Sugimura, K. (2013) · International Journal of Urology · doi:10.1111/iju.12250 · Cited by 34
Spatial oxygenation profiles in tumors during normo- and hyperbaric hyperoxia
Thews, O., & Vaupel, P. (2015) · Strahlentherapie und Onkologie · doi:10.1007/s00066-015-0867-6 · Cited by 33
Koch, C. J., Oprysko, P. R., Shuman, A. L., Jenkins, W. T., Brandt, G., & Evans, S. M. (2002) · PubMed · Cited by 32
Rockwell, S., Irvin, C. G., Kelley, M., Hughes, C. S., Yabuki, H., Porter, E. A., & Fischer, J. J. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90986-r · Cited by 30
Khandelwal, S. R., Kavanagh, B. D., Lin, P., Truong, Q. T., Lu, J., Abraham*, D. J., & Schmidt‐Ullrich, R. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690130 · Cited by 21
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study
Hochberg, F. H., Prados, M., Russell, C. A., Weissman, D., Evans, R. G., Cook, P., Burton, G. V., Eisenberg, P. D., Valenzuela, R. F., & Verkh, L. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005727204169 · Cited by 20
Oxygen Carriers: Are They Enough for Cellular Support?
Johnson, J. L. H. (2017) · Springer series in translational stroke research · doi:10.1007/978-3-319-45345-3_26 · Cited by 9
Therapeutic Targets of FDA-Approved Immunotherapies in Oncology
Markovic, S. N., & Kumar, A. B. (2018) · Springer eBooks · doi:10.1007/978-3-319-70622-1_2 · Cited by 8
Cited by
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01719-5 · Cited by 693
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01305-4 · Cited by 563
Clinical update on head and neck cancer: molecular biology and ongoing challenges
Alsahafi, E., Begg, K., Amelio, I., Raulf, N., Lucarelli, P., Sauter, T., & Tavassoli, M. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1769-9 · Cited by 525
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
Metadata
- Authors
- Graham, K., & Unger, E.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-10
- Volume
- Volume 13
- Pages
- 6049-6058
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2894918092
- Cited by
- 584
- References
- 71
- FWCI
- 14.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.